Type 2 diabetes together with the metabolic syndrome much affect the human health worldwide: 30% global epidemics. In 1931, Elliot P. Joslin wrote: “It is time to move on from diabetes coma to diabetes complications”. Indeed, in 1999 AHA recognized diabetes as a cardiovascular disease. However, new threatening have emerged over the latest years. Thus, more that 50% of the deceased patients affected with the Alzheimer disease showed glycosylated proteins in their necropsies in hippocampal and non-hippocampal brain structures. Thus, a new concept of Diabetes, type 3 Diabetes?, is currently on going. Indeed, the underlying molecular mechanism of such epidemiological association it is almost unknown. On the other hand, patients undergoing a long-standing insulin treatment of their type 1 diabetes showed hyperplastic focus in their retinas, suggesting a hyperproliferative side effect by the chronic insulin treatment. Indeed, insulin resistance it is the earliest pathophysiological event of type 2 diabetes, wich it is associated to for a long while to a compensatory hyperinsulinemia. In 2010, a consensus was reached associating the hyperinsulinemia of the prediabetes or type 2 diabetic patients to an enhanced susceptibility to develop a gastrointestinal tumor.

www.uimp.es

GOBIERNO DE ESPAÑA
MINISTERIO DE EDUCACIÓN, CULTURA Y DEPORTE

INFORMACIÓN GENERAL

→ Hasta el 10 de junio de 2016

Santander
Campus de Las Llamas
Avda. de los Castros, 42
39005 Santander
Tel. 942 29 87 00 / 942 29 87 10
Fax 942 29 87 27
informacion@sa.uimp.es

Madrid
C/ Isaac Peral, 23
28040 Madrid
Tel. 91 592 06 31 / 91 592 06 33
Fax 91 592 06 40 / 91 543 08 97
alumnos@uimp.es

Horario
de 9:00 a 14:00 h
de 16:00 a 18:00 h (excepto viernes)

→ A partir del 13 de junio de 2016

Santander
Palacio de la Magdalena
39005 Santander
Tel. 942 29 88 00 / 942 29 88 10
Fax 942 29 88 20

Horario
de 9:00 a 14:00 h
de 15:30 a 18:00 h (excepto viernes)

PLAZOS

→ Plazo de solicitud de becas

Hasta el día 16 de mayo, para los cursos que comiencen antes del 8 de julio de 2016

Hasta el día 13 de junio, para los cursos que comiencen a partir del día 11 de julio de 2016

→ Apertura de matrícula

Desde el 25 de abril de 2016
(Plazas limitadas)

* Curso acreditado por el Ministerio de Educación, Cultura y Deporte para profesores de enseñanzas no universitarias

NIPO: 041-16-002-1

Transporte oficial

IBERIA

→ Código 630B | Tarifa: A | ECTS: 0,5

@cursosUIMP
fb.com/uimp20

UIMP
Universidad Internacional Menéndez Pelayo



Santander 2016

Encuentro

New complications of the diabetic syndrome in the new millenium: Type 3 Diabetes?

Manuel Benito

Santander
Del 7 al 9 de septiembre de 2016

www.uimp.es

New complications of the diabetic syndrome in the new millenium: Type 3 Diabetes?

Dirección
Manuel Benito
PhD. DPhil. Complutense University & CIBERDEM (ISCIII)
Madrid, Spain

Del 7 al 9 de septiembre de 2016

Miércoles 7

15:30 h | Opening remarks

A. Insulin resistance as the initial pathophysiological feature in type 2

15:45 h | Multiple Roles and Mechanisms Underlying Insulin Resistance in the Metabolic Syndrome
CR Kahn
Chief Academic Officer, Joslin Diabetes Center
Mary K. Iacocca Professor, Harvard Medical School. Boston, U.S.A.

16:45 h | The adipose organ: A source of insulin resistant signals
Ulf Smith
MD, PhD. Professor of Medicine
University of Gothenburg
Sweden

17:45 h | Skeletal muscle insulin sensitivity
Anna Krook
Professor.Department of Physiology and Pharmacology Karolinska Institute
Stockholm, Sweden

Jueves 8

B. Elastoplasticity of pancreatic endocrine cells: The tipe 2 diabetes progression

10:00 h | Molecular basis and regulatory networks of the pancreatic beta cell fate
Lorenzo Pasquali
MD, PhD Germans Trias i Pujol Research Institute

11:00 h | Failure of the compensatory mechanisms of beta-cell insulin secretion: The crossroad of Autophaty/Apoptosis
Manuel Benito

12:00 h | Concluding remarks and Discussion

C. Type 2 diabetes and metabolic syndrome vascular complications

15:00 h | Type 2 diabetes, metabolic syndrome and macrovascular complications
Cristina Rondinone
Vicepresident R&D
Head Cardiometabolic Diseases iMED
Medimmune/Astra-Zeneca
USA

16:00 h | Diabeteic nephropathy
Jesús Egido
Professor and Chairman, Department of Medicine, Autonoma University
Chief, Division of Nephrology and Hypertension
Director Renal, Vascular and Diabetes Research Lab. University Hospital
Fundación Jimenez Diaz & CIBERDEM (ISCIII)
Madrid, Spain

17:00 h | Neurodegeneration in diabetic retinopathy: Therapeutic implications
Rafael Simó Canonge
Head of Diabetes and Metabolism Research Unit
Vall d'Hebron Research Institute
Barcelona & CIBERDEM (ISCIII),
Madrid, Spain

18:00 h | Concluding remarks and Discussion

Viernes 9

D. Neurodegeneration and type 2 diabetes: Type 3 Diabetes?

09:00 h | Molecular basis of neurodegeneration in the Alzheimer disease: The metabolic environment
Jesús Ávila
Associate Professor Ad Honorem CBMSO
(CSIC-UAM)& CIBERNED (ISCIII)
Madrid,Spain

E. Cancer susceptibility associated to insulin resistance and type 2 diabetes

10:00 h | Type 2 diabetes, metabolic syndrome and cancer: The IGFI and insulin connection
Emily Gallagher
Assistant Professor of Medicine and Endocrinology
Division of Diabetes, Endocrinology and Bone Diseases,
Department of Medicine. Mount Sinai School of Medicine
New York, USA

11:00 h | Concluding remarks and discussion

F. Drugs Discovery: New therapeutics approaches

11:15 h | Beyond glucose control: addressing diabetes associated comorbidities
Holger J. Gellermann
Dr. Medical Director
Boehringer Ingelheim Spain

12:15 h | Closure remarks